En vivo
Eli LillyGilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSNThermo FisherThe Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches – Learn Why - Yahoo Finance10x Genomics BlogThis $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - AOL.comEli LillyGilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - StocktwitsPfizerPfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord PharmaEndpoints NewsOtsuka touts new IgAN evidence as it seeks full approval for VoyxactAgilentA Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus - simplywall.stBoston ScientificBoston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs - MassDeviceCharles RiverCharles River Laboratories stock (US1591881009): Insider grant and fresh fund buying keep focus on C - AD HOC NEWSEndpoints NewsActing FDA chief isn't interested in permanent roleClinical OMICsPost-Stroke Arm Immobility Improved with Spinal Cord StimulationLonza NewsStipple Bio and Lonza Agree to Focus on Advancing Oncology ADC Therapies - Genetic Engineering and Biotechnology News
Endpoints News 25 feb 2026

Charles River sells its CDMO and European discovery businesses

Charles River sells its CDMO and European discovery businesses

Original
Contenido no disponible. Consulta la fuente original.